Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

What makes Owkin different?

Unparalleled access to multimodal patient data

  • Privacy-enhanced access to the most up-to-date patient data and samples
  • Research-grade longitudinal data curated with Principal Investigators (PIs)
  • Multimodal patient data to capture the full heterogeneity of disease 
Find out more
Button

Cutting-edge AI

  • Interpretable predictive models validated by medical experts 
  • Multiscale causal AI to connect the dots across cellular, molecular, and tissue scales, capturing the causal links of complex biology
  • Integrating prior knowledge with large language models to strengthen our causal predictions 
Find out more
Button

Grounded in biology

  • Experimentally validating AI-derived subgroups and candidate drug targets 
  • Lab-in-the-loop: integrating wet lab data and AI to create a powerful feedback loop to accelerate R&D
  • Understanding cancer and tumor microenvironment interactions at cellular level 
Find out more
Button
Video
Understanding Owkin

We are a full-stack AI biotech

By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients.

Multimodal patient dataAI subgroup discoveryAI drug discoveryAI drug developmentAI diagnostics

Multimodal patient data

Owkin works with top academic centers to curate, enrich and generate deep, multimodal data that is AI ready.

We are building a technology platform called Abstra that will host a metadata catalog to enable researchers and data scientists to discover collaborators and datasets, enhancing and expediting AI biomedical research.

Federated research networkSubstraAbstraConsortiaFederated learning

Subgroup discovery

We apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice. 

Subgroup discovery

AI drug discovery 

Our drug discovery engines leverage our expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through our AI engines, we deliver novel drug targets and optimize drug positioning.

Subgroup discoveryTarget discoveryIndication discovery

AI drug development 

We combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

AI external control armsInclusion criteria modelsData-driven covariate adjustment

AI diagnostics

Our AI diagnostics help pre-screen for biomarkers, and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

MSIntuit™ CRCRlapsRisk™ BCCompanion diagnostics 

Why work with Owkin

02
Owkin is founder-led
Thomas Clozel, MD, Oncologist, and Gilles Wainrib, PhD, Professor of Machine Learning
06
Global reach
Locations in Boston, New York, London, Paris, Nantes, and Geneva
02
Trusted by top 8 biopharmas
Strategic deals with:
Sanofi - AI drug discovery
BMS - AI drug development 
#
Cutting-edge science & AI
Publications in top scientific journals like Nature Medicine, Nature Communications, and Hepatology
304
Well-funded
Million dollars raised from leading biopharma companies (Sanofi & BMS) and venture funds (Fidelity, Google Ventures & BPI, among others)
Play

We are hiring

Join our team

We are a community of diverse people bringing our energy and skills to find the right treatment for every patient.

Careers at Owkin

Discover our groundbreaking science

PUBLICATION
PyDESeq2: a python package for bulk RNA-seq differential expression analysis
September 5, 2023
Press release
Owkin signs research agreement with Genmab A/S to explore the biological profiles of cancer patients to improve treatments
September 19, 2023
PublicationsLatest news & blog

Testimonial

"I'm excited about the Sanofi and Owkin collaboration and its potential to transform drug discovery. Owkin's data network and AI capabilities, combined with Sanofi's expertise, can potentially lead to new treatments and better patient outcomes."
Frank Nestle, MD
Global Head of Research and Chief Scientific Officer, Sanofi

Testimonial

"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."
Professor Miriam Merad, MD, PhD
Director of the Precision Immunology Institute, Mount Sinai School of Medicine

Testimonial

"We look forward to collaborating with Owkin to extend our applications of AI and machine learning to enhance our discovery and development programs with high-quality, diverse data from clinical and real world sources."
Venkat Sethuraman, MD
Senior Vice President, Global Biometrics and Data Sciences, Bristol Myers Squibb

Testimonial

“Without federated learning, most biomedical data would likely remain unused and unavailable to construct the next generation of predictive algorithms.”
Olivier Elemento, MD, PhD
Director of Caryl and Israel Englander Institute for Precision Medicine, Cornell University

Testimonial

"I'm excited about the Sanofi and Owkin collaboration and its potential to transform drug discovery. Owkin's data network and AI capabilities, combined with Sanofi's expertise, can potentially lead to new treatments and better patient outcomes."
Frank Nestle, MD
Global Head of Research and Chief Scientific Officer, Sanofi